肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证

doi:10.3969/j.issn.1672-5069.2022.06.023

摘要/Abstract

摘要： 目的探讨建立肝硬化患者门静脉血栓形成(PVT)列线图预测模型及外部验证情况。方法 2010年1月～2021年10月我院收治的肝硬化伴或不伴PVT患者,收集一般资料、血清学指标、超声等影像学资料。对建模组数据应用Lasso回归和多因素Logistic回归模型筛选出肝硬化并发PVT的独立危险因素并建立列线图预测模型,应用验证组数据对该模型进行外部验证。结果肝硬化并发PVT患者独立危险因素为脾切除史、门静脉主干内径和脾静脉直径(P＜0.05);在验证人群,对列线图预测模型进行外部验证,其ROC曲线下面积为0.751(95%CI:0.674～0.827),预测模型区分度良好,经Hosmer-Lemeshow检验,P值为0.170,提示预测模型的校准度较高。结论我们开发了一种易于使用的肝硬化并发PVT形成的列线图预测模型,可以协助临床医护人员筛选高PVT风险人群,制定及时、个性化的诊治方案,希望最终改善患者预后。

关键词: 肝硬化, 门静脉血栓形成, 列线图, 预后

Abstract: Objective The aim of this study was to establish a nomogram for predicting portal venous thrombosis (PVT) in patients with liver cirrhosis (LC). Method 1000 patients with LC were enrolled in our hospital between January 2010 and October 2021, and the clinical materials, including general data, serological indicators, ultrasonography and CT imaging were collected. A nomogram model was established by Lasso and multivariate Logistic regression analysis. Results The risk factours included splenectomy, widened portal vain diameters and splenic vain diameters in patients with liver cirrhosis complicated by PVT (P＜0.05); in the external validation population, the AUC of the nomogram prediction model was 0.751 (95%CI:0.6740-0.827) with a good discrimination (P=0.170, by Hosmer-Lemeshow test) , suggesting a high reliability of the model. Conclusion We establish an easy-to-use nomogram to predict the PVT formation in patients with cirrhosis. This nomogram might help clinicians screen patients at high risk of PVT, make in timely and individualized clinical decisions to improve outcomes of them.

Key words: Liver cirrhosis, Portal vein thrombosis, Nomogarms, Prognosis

朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.

Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis[J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.

参考文献

[1] Francesco V, Gino CR, Hugh CS, et al. Portal vein thrombosis relevance on liver cirrhosis: Italianvenous thrombotic events registry. Intern Emerg Med, 2016, 11(8):1059-1066.
[2] 祁兴顺, 杨玲. 肝硬化门静脉血栓管理专家共识(2020年,上海). 临床肝胆病杂志, 2020, 36(12):2667-2674.
[3] Wang L, Guo X, Xu X, et al. Anticoagulationfavors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: Results of a Meta-analysis. Adv Ther, 2021, 38(1):495-520.
[4] 徐小元, 丁惠国, 李文刚,等. 肝硬化诊治指南. 实用肝脏病杂志, 2019, 22(6):770-786.
[5] Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol, 2004, 40(5):736-741.
[6] Maruyama H, Okugawa H, Takahashi M, et al. De novo portal vein thrombosis in virus-related cirrhosis: Predictive factors and long-term outcomes. Am J Gastroenterol, 2013, 108(4):568-574.
[7] Dong F, Luo SH, Zheng LJ, et al. Incidence of portal vein thrombosis after splenectomy and its influence on transjugular intrahepatic portosystemic shunt stent patency. World J Clin Cases, 2019, 7(17):2450-2462.
[8] Stine JG, Jennifer W, Shah PM, et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study. Liver Int, 2018, 38(1):94-101.
[9] 陈帅, 杨长青. 门静脉血栓病因及危险因素研究进展. 实用肝脏病杂志, 2019, 22(6):761-764.
[10] Basili S, Carnevale R, Nocella C. Serumalbumin is inversely associated with portal vein thrombosis in cirrhosis. Hepatol Commun, 2019, 3(4):504-512.
[11] Nery F, Correia S, Macedo C, et al. Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. AlimentPharmacol Ther, 2019, 49(5):582-588.
[12] 热那特·克力木, 吐尔干艾力·阿吉, 邵英梅. 肝硬化并发门静脉血栓患者临床特征及其危险因素分析. 实用肝脏病杂志, 2020, 23(3):401-404.
[13] 吕少诚, 顾万清. 肝硬化患者脾切除术后门静脉血栓的防治研究进展. 中华肝胆外科杂志, 2015, 21(1):59-63.
[14] De'angelis N, Abdalla S, Lizzi V, et al. Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy. Surgery, 2017, 162(6):1219-1230.
[15] Matsui T, Usui M, Wada H, et al. Plateletactivation assessed by glycoprotein VI/platelet ratio is associated with portal vein thrombosis after hepatectomy and splenectomy in patients with liver cirrhosis. Clin Appl Thromb Hemost, 2018, 24(2):254-262.
[16] Kuroki T, Kitasato A, Tokunaga T, et al. Predictors of portal and splenic vein thrombosis after laparoscopic splenectomy: a retrospective analysis of a single-center experience. SurgToday, 2018, 48(8):804-809.
[17] Satoyuki O, Akira Y, Atsushi J, et al. Splenicvein diameter is a risk factor for the portal venous system thrombosis after partial splenic artery embolization. CardioVasc Inter Rad, 2021, 44(6):921-930.
[18] 邱婷, 金燕, 吕颐菲, 等. 肝硬化并发门静脉血栓危险因素的Logistic回归分析. 实用肝脏病杂志, 2018, 21(6):916-919.
[19] Wang XY, Wang HZ, Junhou L, et al. Erythropoietin-modified mesenchymal stem cells enhance anti-fibrosis efficacy in mouse liver fibrosis model. Tissue Eng Regen Med, 2020, 17(5):683-693.
[20] Dong G, Huang XQ, Zhu YL, et al. Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis. Ann Transl Med, 2021, 9(4):289.
[21] Ahmed AR, Nasser M, Rania E, et al. De novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the model for end-stage liver disease scoring system. Eur J Gastroenterol Hepatol, 2015, 27(5):585-592.
[22] Kuroki T, Kitasato A, Tokunaga T, et al. Predictors of portal and splenic vein thrombosis after laparoscopic splenectomy: a retrospective analysis of a single-center experience. Surg Today, 2018, 48(8):804-809.
[23] Anton A, Campreciós G, Pérez-Campuzano V, et al. The pathophysiology of portal vein thrombosis in cirrhosis: Getting deeper into Virchow's triad. J Clin Med, 2022, 11(3):800-811.